Heart drug trial aims to shield young duchenne patients from cardiac damage
NCT ID NCT01648634
Summary
This study tested whether a blood pressure/heart rate medication called nebivolol could prevent heart muscle weakness in boys with Duchenne muscular dystrophy. Fifty-one boys aged 10-15 with Duchenne but normal heart function at the start took either nebivolol or a placebo pill daily. Researchers measured whether the drug could delay or prevent the development of heart failure, a common and serious complication of Duchenne.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Armand Trousseau Hospital
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.